Home › NCT06982508

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study

Who can join

Ages 18 to 75 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Visual acuity \> 20/60 in both eyes with or without corrective lenses

Exclusion Criteria:

* Type 2 diabetes
* Active liver disease
* Any clinically significant macular pathology

About the study

The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are:

Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants.

Participants will:

Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels

What is being tested

• Obicetrapib 10mg (drug)
• Placebo (drug)

Sponsor: NewAmsterdam Pharma · Participants: 100 · Started: Sep 9, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06982508

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.